Focused Wealth Management Inc Invests $1.48 Million in Sarepta Therapeutics Inc (SRPT)

Focused Wealth Management Inc bought a new stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) in the 3rd quarter, Holdings Channel reports. The firm bought 9,181 shares of the biotechnology company’s stock, valued at approximately $1,483,000.

Several other institutional investors have also recently bought and sold shares of SRPT. FMR LLC raised its stake in Sarepta Therapeutics by 1.4% during the 3rd quarter. FMR LLC now owns 9,887,230 shares of the biotechnology company’s stock valued at $1,596,887,000 after acquiring an additional 137,351 shares during the last quarter. BlackRock Inc. raised its stake in Sarepta Therapeutics by 2.6% during the 3rd quarter. BlackRock Inc. now owns 4,808,259 shares of the biotechnology company’s stock valued at $776,581,000 after acquiring an additional 121,003 shares during the last quarter. FIL Ltd raised its stake in Sarepta Therapeutics by 67.6% during the 3rd quarter. FIL Ltd now owns 1,793,701 shares of the biotechnology company’s stock valued at $289,701,000 after acquiring an additional 723,542 shares during the last quarter. Jennison Associates LLC raised its stake in Sarepta Therapeutics by 0.5% during the 3rd quarter. Jennison Associates LLC now owns 1,219,503 shares of the biotechnology company’s stock valued at $196,962,000 after acquiring an additional 5,604 shares during the last quarter. Finally, Eagle Asset Management Inc. raised its stake in shares of Sarepta Therapeutics by 55.1% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,067,318 shares of the biotechnology company’s stock worth $172,382,000 after buying an additional 379,162 shares in the last quarter. 92.04% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently issued reports on SRPT shares. Morgan Stanley raised Sarepta Therapeutics from an “equal weight” rating to an “overweight” rating and set a $163.00 target price for the company in a research note on Wednesday, August 1st. Cantor Fitzgerald started coverage on Sarepta Therapeutics in a research note on Monday, October 1st. They set an “overweight” rating and a $217.00 target price for the company. HC Wainwright set a $267.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 9th. Credit Suisse Group started coverage on Sarepta Therapeutics in a research note on Thursday, September 6th. They set an “outperform” rating and a $178.00 target price for the company. Finally, Bank of America started coverage on Sarepta Therapeutics in a research note on Friday, September 14th. They set a “buy” rating and a $199.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-three have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $169.19.

SRPT opened at $119.35 on Monday. The company has a market capitalization of $7.98 billion, a P/E ratio of -72.77 and a beta of 1.59. The company has a debt-to-equity ratio of 0.65, a quick ratio of 7.84 and a current ratio of 8.85. Sarepta Therapeutics Inc has a 1-year low of $50.68 and a 1-year high of $176.50.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.29). The firm had revenue of $78.49 million during the quarter, compared to analyst estimates of $78.84 million. Sarepta Therapeutics had a negative return on equity of 23.67% and a negative net margin of 89.46%. As a group, equities research analysts forecast that Sarepta Therapeutics Inc will post -4.38 earnings per share for the current fiscal year.

In other Sarepta Therapeutics news, CFO Sandesh Mahatme sold 107,524 shares of the stock in a transaction on Wednesday, October 24th. The stock was sold at an average price of $127.74, for a total transaction of $13,735,115.76. Following the sale, the chief financial officer now owns 48,381 shares in the company, valued at approximately $6,180,188.94. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Douglas S. Ingram bought 16,695 shares of the stock in a transaction on Tuesday, October 30th. The shares were bought at an average price of $120.39 per share, for a total transaction of $2,009,911.05. Following the acquisition, the chief executive officer now owns 412,811 shares in the company, valued at approximately $49,698,316.29. The disclosure for this purchase can be found here. Corporate insiders own 7.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Focused Wealth Management Inc Invests $1.48 Million in Sarepta Therapeutics Inc (SRPT)” was published by WKRB News and is the property of of WKRB News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.wkrb13.com/2018/11/26/focused-wealth-management-inc-invests-1-48-million-in-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

See Also: Hedge Funds – How They Work For Investors

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply